Dermapharm Holding SE / Key word(s): Development of Sales
Disclosure of Insider Information pursuant to Section 17 (1) 1 of the Regulation (EU)
Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million € contribution to sales in 2021
Grünwald, February 12, 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) expects the cooperation with BioNTech SE, Mainz, in the production of the Covid-19 vaccine Comirnaty(R) to contribute a high double-digit million € amount to the consolidated sales of the Dermapharm Group in the full year 2021. This is the result of a current plan for vaccine production approved today by the Management Board of Dermapharm Holding SE. Among other things, it includes the establishment of additional production capacities at the Reinbek site, which are scheduled to go into operation in May 2021.
>End of the ad hoc announcement<
12-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Dermapharm Holding SE
+49 (0)89 64 86-0
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID:
End of Announcement
DGAP News Service